<DOC>
	<DOC>NCT00600509</DOC>
	<brief_summary>Double-blind, randomized, placebo-controlled, multi center trial to evaluate the efficacy and safety of levetiracetam as adjunctive treatment in adult Japanese epileptic subjects with partial onset seizures.</brief_summary>
	<brief_title>Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>simple and/or complex partial seizures with or without secondary generalization, and first partial seizure &gt;= 2 years before selection visit; seizures classifiable according to the ILAE classification; minimum of 12 partial seizures per 12 weeks with a minimum of two partial seizures per 4 weeks from the selection visit to the end of the baseline period ; exposed to two or more standard AEDs; taking up to three of the standard AEDs, at the initiation of the trial. medication influencing the CNS, except for medication taken for antiepileptic treatment; partial seizures uncountable due to clustering, including status epileptics, during the 3 months prior to the selection visit; history of cerebrovascular disease including transient ischemic attack (TIA) and progressive cerebral disorder or progressive neurological disorder; presence or history of any clinically significant allergic condition and complication or history of significant alcohol abuse or drug abuse in the past.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>